1. Breast Cancer Metastasis
Metastasis is a major cause of mortality in breast cancer, and understanding the molecular mechanisms that drive tumour dissemination remains a critical challenge. Our research focuses on identifying ubiquitin-regulatory mechanisms that control breast cancer progression, migration, and invasion. We have identified EIF3H, a JAMM-family deubiquitinase (DUB), as an important regulator of breast cancer progression and are investigating its role in oncogenic signaling and metastatic behaviour. Our ongoing work aims to understand the therapeutic potential of targeting EIF3H and related ubiquitin-regulatory pathways to develop new strategies against metastatic breast cancer.
Related Article: Deubiquitinating enzymes in breast cancer: in silico analysis of gene expression and metastatic correlation. J Biomol Struct Dyn. 2026 Feb;44(2):612-621. doi: 10.1080/07391102.2024.2439046.
Related preprint: bioRxiv, 2025.08. 24.672041. https://doi.org/10.1101/2025.08.24.672041
2. Telomerase Regulation
Telomerase activation is a fundamental feature of cancer that enables tumour cells to maintain their proliferative potential. Our laboratory investigates how deubiquitinases regulate telomerase and hTERT expression in cancer. We identified the proteasome-associated DUB PSMD7 as a regulator of hTERT and telomerase activity and are investigating the molecular pathways underlying this regulation. This research aims to establish how ubiquitin-dependent mechanisms contribute to telomere maintenance and cancer progression and to evaluate their potential as therapeutic vulnerabilities.
3. Cancer Metabolism and Metabolic Reprogramming
Cancer cells undergo extensive metabolic adaptations to support rapid growth, survival, and resistance to stress. We investigate how DUBs and ubiquitin-dependent pathways regulate cancer-associated metabolic processes. Our research particularly focuses on understanding the relationship between ubiquitin signaling and pathways involved in nucleotide metabolism and cellular metabolic adaptation. By combining functional genomics with molecular and metabolic approaches, we aim to identify metabolic vulnerabilities that can be therapeutically exploited in cancer.
4. Chemoresistance
Therapy resistance remains a major obstacle to effective cancer treatment and is a significant contributor to disease recurrence. Our laboratory investigates how DUBs regulate cellular responses to anticancer therapies and promote tumour cell survival. We are interested in identifying DUB–substrate regulatory networks associated with chemoresistance and understanding how these pathways can be therapeutically targeted. Our broader goal is to develop selective DUB-targeting strategies that can potentially improve responses to existing cancer therapies.
Related review: Drug Discov Today. 2025 Mar 19:104339. https://doi.org/10.1016/j.drudis.2025.104339.
5. Cancer Stem Cells and Glioblastoma
Cancer stem cells contribute to tumour initiation, recurrence, progression, and therapeutic resistance. We investigate the role of deubiquitinases in regulating cancer stem cell properties, with a particular focus on glioblastoma. Our work on USP46 aims to understand its contribution to glioblastoma stem cell maintenance and tumour progression. In collaboration with Dr. K. Somasundaram, IISc, we integrate molecular biology, and cellular approaches to identify mechanisms that sustain cancer stemness and explore potential therapeutic vulnerabilities.
6. Head and Neck Cancer
We are investigating molecular and circulating biomarkers in head and neck squamous cell carcinoma (HNSCC), with a focus on circulating tumour DNA (ctDNA) and circulating microRNAs. This work aims to identify molecular signatures associated with disease characteristics and treatment outcomes. Our long-term objective is to develop minimally invasive biomarkers with potential applications in disease detection, prognostic assessment, and treatment monitoring.
7. Targeted Protein Degradation and PROTACs
We have recently expanded our research into targeted protein degradation and PROTAC (proteolysis-targeting chimera) technology as an emerging approach for cancer therapy. Our research focuses on identifying breast cancer-selective E3 ubiquitin ligases and therapeutically relevant protein targets that could be exploited for targeted protein degradation. By integrating cancer genomics, functional dependency data, and computational approaches, we aim to uncover novel therapeutic vulnerabilities and establish a foundation for the rational development of cancer-selective PROTAC strategies.